Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Understanding genotype to predict phenotype
3. The path from genotype to phenotype
4. A better understanding of phenotype is required
5. Medicine has always been "personalized"
6. The "omics" (molecules) we should measure
7. Proteomics
8. A technology to address the proteome complexity
9. SomaLogic's version of SELEX - SOMAmers
10. The privileged 5 position of pyrimidines
11. "Pull downs" show SOMAmer specificity
12. Crystal structures (1)
13. Crystal structures (2)
14. Crystal structures (3)
15. Crystal structures (4)
16. SOMAscan proteomic assay- from protein to DNA
17. SOMAmers are measured by DNA techniques
18. SOMAscan today
19. Using SOMAscan (lung cancer)
20. Using SOMAscan (non-small cell lung cancer)
21. Lung cancer serum biomarkers
22. Diagnostic performance of 7-marker classifier
23. Using SOMAscan (cardiovascular risk)
24. Using SOMAscan (pre-term birth)
25. Using SOMAscan (pancreatic cancer)
26. Using SOMAscan (Mesothelioma)
27. Using SOMAscan - diagnostic pipeline
28. Future goals-wellness chip, longitudinal monitoring
29. Longitudinal blood tests can detect cancer early
30. Longitudinal blood tests can facilitate Wellness
31. Conclusions
32. One last thought
33. Acknowledgements

Topics Covered

• The proteomic revolution
• Proteomics is the best measure of phenotype (biomarkers)
• Slow Off-rate Modified Aptamers (SOMAmers) are breakthrough protein binding reagents
• SOMAmers are multiplexed to perform SOMAscan assay, which measures >1000 proteins in small sample volumes using DNA measurement tools to identify and quantify proteins bound by SOMAmers
• Applications of SOMAscan to date include finding valid protein biomarkers for lung cancer, cardiovascular risk, pre-term birth, pancreatic cancer, mesothelioma, and many other diseases and conditions
• Ability to do comprehensive longitudinal proteomics studies will revolutionize medicine

Links

Series:

• Biomarkers

Categories:

• Biochemistry
• Cell Biology
• Omics & Systems Biology
• Pharmaceutical Sciences

Therapeutic Areas:

• Oncology

Talk Citation

Publication History

• Published on September 27, 2012

Financial Disclosures

• Dr. Larry Gold has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.